Stock Events

Exact Sciences 

€42.71
246
+€1.66+4.04% 今天

统计数据

当日最高
42.71
当日最低
42.71
52周最高
-
52周最低
-
成交量
0
平均成交量
-
市值
8.55B
市盈率
-35.61
股息收益率
-
股息
-

收益

8May已确认
Q3 2022
Q4 2022
Q1 2023
Q2 2023
Q3 2023
Q4 2023
Q1 2024
-1.12
-0.84
-0.55
-0.27
预期每股收益
-0.48
实际每股收益
-0.6

人们还关注

此列表基于关注EXK.F的Stock Events用户的观察列表。这不是投资建议。

竞争者

这个列表是基于最近市场事件的分析。这不是投资建议。

分析师评级

75.4平均价格目标
最高估值为 €85。
来自过去6个月内的 5 个评级。这不是投资建议。
买入
100%
持有
0%
卖出
0%

关于

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services. The company's pipeline products focus on enhancing the Cologuard test's performance characteristics and developing blood and other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research, and Johns Hopkins University. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.
Show more...
首席执行官
Mr. Kevin T. Conroy
员工
6500
国家
US
ISIN
US30063P1057
WKN
000590273

上市公司